Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Limited Liability Company KlinMed Consulting
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim The primary objective of this study was to comparatively assess the effects of levosimendan and dobutamine on RVEF, right ventricular diastolic function, and hormonal balance in patients with biventricular heart failure. The secondary objective was to investigate the relationship between the RVEF and the peak systolic velocity (Sa), an indicator of right ventricular systolic function, as measured by tissue Doppler echocardiography from the tricuspid annulus, and by the tricuspid annular plane systolic excursion (TAPSE). Material and Methods The population of this cross-sectional, single-center, prospective study was comprised of 81 patients, who between December 2019 and January 2022, applied to the study health institution with diagnosis of ADHF. The study sample included 67 biventricular heart failure patients with left ventricular ejection fraction (LVEF) <35% and RVEF <50%, as measured by the ellipsoidal shell model, and who met the other study inclusion criteria. Of these 67 patients, 34 were treated with levosimendan, and 33 were treated with dobutamine. RVEF, LVEF, Sa, peak early (Ea) and peak late (Aa) annular velocities, Ea/Aa ratio, TAPSE, systolic pulmonary artery pressure (SPAP), n-terminal pro-brain natriuretic peptide (NT-pro BNP), and functional capacity (FC) were measured before treatment and at 48 hrs of treatment. The within group pre- and post-treatment differences (?s) of these variables were compared. Results RVEF, SPAP, and BNP, and FC significantly improved in both treatment groups (p<0.05 for all). Sa (p<0.01), TAPSE (p<0.01), LVEF (p<0.01), and Ea/Aa (p<0.05) improved only in the levosimendan group. The pre- and post-treatment ?s for RVEF, LVEF, SPAP, Sa, TAPSE, FC, and Ea/Aa were higher in the levosimendan group than in the dobutamine group (p<0.05 for all). Conclusion Compared to dobutamine, levosimendan produced greater improvement in right ventricular systolic and diastolic function in patients with biventricular heart failure and in need of inotropic therapy support. © 2023 Limited Liability Company KlinMed Consulting. All rights reserved.
Açıklama
Anahtar Kelimeler
dobutamine, heart failure, Levosimendan, right ventricular systolic dysfunction, amino terminal pro brain natriuretic peptide, dobutamine, levosimendan, cardiovascular agent, dobutamine, simendan, acute heart failure, aged, Article, cardiovascular parameters, clinical assessment, clinical feature, comparative study, controlled study, cross-sectional study, demographics, disease association, drug dose titration, drug effect, echocardiography, ellipsoidal shell model, female, functional status, heart left ventricle ejection fraction, heart left ventricle failure, heart right ventricle diastolic function, heart right ventricle ejection fraction, heart right ventricle failure, heart right ventricle function, hormone determination, human, infusion therapy, loading drug dose, major clinical study, male, medical parameters, model, peak annular velocity, peak early annular velocity, peak systolic velocity, prospective study, pulmonary artery systolic pressure, tissue Doppler imaging, treatment outcome, tricuspid annular plane systolic excursion, tricuspid annulus, heart failure, heart left ventricle function, heart stroke volume, Cardiovascular Agents, Cross-Sectional Studies, Dobutamine, Heart Failure, Humans, Prospective Studies, Simendan, Stroke Volume, Ventricular Function, Left, Ventricular Function, Right
Kaynak
Kardiologiya
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
63
Sayı
2
